The efficacy of omalizumab treatment in patients with nonatopic severe asthma
Main Article Content
Keywords
ACT, nonatopic asthma, omalizumab, severe asthma
Abstract
Introduction: Nonatopic asthmatic patients generally have more severe clinical manifestations, frequently accompanied by chronic sinusitis and nasal polyps, with more limited therapeutic options as compared to atopic asthmatic patients. This has led to a search for novel therapeutic approaches, including omalizumab, for nonatopic asthmatic patients who are not adequately controlled with current therapies.
Materials and Methods: In this retrospective study undertaken between August 1, 2020, and December 31, 2021, at a tertiary allergy clinic, data from 61 patients with nonatopic asthma inadequately controlled with optimum therapy was examined.
Results: A total of 61 patients with severe asthma were included in the study [Female: 48 (78.7%), male: 13 (21.3%, mean age: 49 (18–71) years]. The mean duration of asthma was 60 (18–160) months. A statistically significant increase in Forced expiratory volume (FEV1per second), forced vital capacity (FVC), and asthma control test (ACT) scores were found after 1 year of omalizumab treatment (p ˂ 0.001, for all parameters). Omalizumab treatment was associated with a significant decrease in the number of asthma exacerbations, asthma-related hospitalizations, duration of hospitalizations, and several unplanned emergency room visits after 1 year (p ˂ 0.001, for all parameters). A 1-year treatment with omalizumab led to significant changes in eosinophil counts and serum IgE levels (p ˂ 0.001 and ˂ 0.001, respectively).
Conclusion: In the severe atopic asthma patient group, omalizumab treatment provided similar clinical benefits to those observed in patients with severe atopic asthma, suggesting that it may be a useful therapeutic option in patients with nonatopic asthma who failed to benefit from treatments with steps 4 and 5.
References
2. Fick RB, Jr. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulm Med. 1999;5(1):76–80. 10.1097/00063198-199901000-00013
3. Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med. 2005;11(1):27–34. 10.1097/01.mcp.0000147860.83639.30
4. El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol. 2016;50(1):84–96. 10.1007/s12016-015-8490-y
5. Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma (GINA) Strategy 2021-Executive summary and rationale for key changes. Eur Respir J. 2021;59:2102730. 10.1183/13993003.02730-2021
6. Pillai P, Chan YC, Wu SY, Ohm-Laursen L, Thomas C, Durham SR, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016;48(6):1593–601. 10.1183/13993003.01501-2015
7. de Llano LP, Vennera Mdel C, Alvarez FJ, Medina JF, Borderias L, Pellicer C, et al. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013;50(3):296–301. 10.3109/02770903.2012.757780
8. Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J. 2000;16(4):609–14. 10.1034/j.1399-3003.2000.16d07.x
9. Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol. 2011;7(1):9. 10.1186/1710-1492-7-9
10. van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest. 2011;139(1):190-3. 10.1378/chest.10-0128
11. Sugino Y, Sanda R, Takagi Y, Kato M, Ohta A, Okumura J, et al. A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens. Arerugi. 2010;59(11):1572–79.
12. Celebi Sozener Z, Aydin O, Misirligil Z, Mungan D, Demirel YS, Celik GE, et al. Omalizumab in non-allergic Asthma: A report of 13 cases. J Asthma. 2018;55(7):756–63. 10.1080/02770903.2017.1362427
13. Ish P, Malhotra N, Gupta N. GINA 2020: what's new and why? J Asthma. 2021;58(10):1273–77. 10.1080/02770903.2020.1788076
14. Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, et al. The skin prick test-European standards. Clin Transl Allergy. 2013;3(1):3. 10.1186/2045-7022-3-3
15. Nguyen VN, Chavannes N, Le LT, Price D. The asthma control test (act) as an alternative tool to global initiative for asthma (GINA) guideline criteria for assessing asthma control in Vietnamese outpatients. Prim Care Respir J. 2012;21(1):85–9. 10.4104/pcrj.2011.00093
16. Easthope S, Jarvis B. Omalizumab. Drugs. 2001;61(2):253–60. 10.2165/00003495-200161020-00008
17. MacGlashan DW Jr., Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158(3):1438–45.
18. Berger P, Scotto-Gomez E, Molimard M, Marthan R, Le Gros V, Tunon-de-Lara JM. Omalizumab decreases nonspecific airway hyperresponsiveness in vitro. Allergy. 2007;62(2):154–61. 10.1111/j.1398-9995.2006.01243.x
19. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117(6):1493–99. 10.1016/j.jaci.2006.02.028
20. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–90. 10.1067/mai.2001.117880
21. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–93. 10.1164/rccm.200312-1651OC
22. Saffar AS, Alphonse MP, Shan L, Hayglass KT, Simons FE, Gounni AS. IgE modulates neutrophil survival in asthma: role of mitochondrial pathway. J Immunol. 2007;178(4):2535–41. 10.4049/jimmunol.178.4.2535
23. Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, Siraganian RP, et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity. 2001;14(6):801–11. 10.1016/s1074-7613(01)00159-5
24. Oliver JM, Tarleton CA, Gilmartin L, Archibeque T, Qualls CR, Diehl L, et al. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol. 2010;151(4):275–84. 10.1159/000250436
25. Burrows B, Halonen M, Lebowitz MD, Knudson RJ, Barbee RA. The relationship of serum immunoglobulin E, allergy skin tests, and smoking to respiratory disorders. J Allergy Clin Immunol. 1982;70(3):199–204. 10.1016/0091-6749(82)90042-2
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.